- Childhood cancers
- Colon cancer
- Gastrointestinal Carcinoid Tumor
- Small Intestine
- Head and Neck
- HIV and AIDS Related
- Kaposi Sarcoma
- Multiple Myeloma
- Metastatic Cancer
- Recurring Cancers
- Secondary (Metastatic)
- Squamous Cell
- Adjuvant Chemotherapy
- Biological Therapy
- Cesium Chloride
- Docetaxel (Taxotere)
- Doxorubicin (Adriamycin)
- Oral Chemotherapy
- Paclitaxel (Taxol)
- Pixantrone (Pixurvi)
- Platinum-based chemotherapy
- Chemotherapy Regimens
- Clinical Trials
- Gene Therapy
- Gerson Therapy
- Hormone Therapy
- Laser Therapy
- Platinum-based Therapy
- Targeted Therapies
- Pain Management
- Proton Therapy
- Watchful Waiting
Abraxane Cancer Treatment
Abraxane is the brand name for an injectable cancer treatment drug also called albinum-based paclitaxel.
Paclitaxel (Taxol) is a widely used chemotherapy drug, but Abraxane is different because in this formulation, a highly water-soluble human blood protein called albinum is attached to the paclitaxel. Not only does the albinum make paclitaxel more easily absorbed (bioavailable) by the body, it is also believed to make the drug far less toxic and much more effective than standard paclitaxel.
- Class: Cytotoxic antimicrotubule agent
- Mechanism of action: Abraxane is believed to work by exploiting an albinum-specific cellular pathway in order to deliver the drug into a tumor cell.
- Treatment type: Chemotherapy
- US approval: 2005
- Synonyms: Paclitaxel Albumin-stabilized Nanoparticle Formulation, ABI-007, nanoparticle paclitaxel, nab-paclitaxel
- FDA Use-in-Pregnancy Rating: Category D
What Abraxane is effective for and why
The manufacturer of Abraxane, Abraxis Bioscience, is currently investigating the safety and efficacy of Abraxane against non-small-cell lung, malignant melanoma, pancreatic, and stomach or gastric cancers.
Side effects of Abraxane
Although thought to be significantly less toxic than standard paclitaxel, Abraxane does cause side effects in some patients. Those side effects include easy bruising or bleeding, neutropenia, leucopenia, anemia, severe asthenia, hair loss, diarrhea, nausea, infections, and sensory neuropathy.
- Boyiadzis, Michael M. et al. Hematology-Oncology Therapy. 2007. New York: McGraw Hill, Medical Publishing Division.
- Guide to Cancer Drugs, American Cancer Society
- Cancer Drug Manual, BC Cancer Agency
- National Cancer Institute: Abraxane
Significant studies and papers relating to Abraxane
- Garber, Ken. "Improved Paclitaxel Formulation Hints at New Chemotherapy Approach." J Natl Cancer Inst (2004) 96(2): 90-91.doi: 10.1093/jnci/96.2.90
- Gradishar WJ et al. "Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer." J Clin Oncol 2005 Nov 1;23(31):7794-803.
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.